Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractionated Docetaxel and Radium 223 in mCRPC
NCT03737370Phase 1Completed
- Sponsor
- Tufts Medical Center
- Start
- Jan 2018
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of radium-223 dichloride and docetaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Tufts Medical Center. Started Jan 2018; status: completed.
02
Drugs
radium-223 dichloridedocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03737370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737370.